RLYB
Rallybio CorpKey Statistics
About Rallybio Corp
Rallybio Corp is a clinical-stage biotechnology company dedicated to developing innovative therapies for rare diseases with a particular emphasis on unmet needs in immunology and hematology. The company features a promising pipeline of biologic drug candidates progressing through various clinical stages, supported by a highly experienced management team with extensive industry expertise. Strategic partnerships enhance Rallybio's ability to deliver transformative treatments, reinforcing its commitment to underserved therapeutic areas. With a clear focus on improving patient outcomes, Rallybio is strategically positioned to make a meaningful impact in the healthcare landscape while advancing toward commercial viability.
Fundamentals
| Revenue (TTM) | 858,000 |
| Gross Profit (TTM) | $-17.54M |
| EBITDA | $-31.27M |
| Operating Margin | -2888.00% |
| Return on Equity | -15.00% |
| Return on Assets | -30.10% |
| Revenue/Share (TTM) | $0.15 |
| Book Value | $10.97 |
| Price-to-Book | 0.86 |
| Price-to-Sales (TTM) | 87.05 |
| EV/Revenue | - |
| EV/EBITDA | -1.41 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 484.20% |
| Shares Outstanding | $5.29M |
| Float | $2.86M |
| % Insiders | 4.16% |
| % Institutions | 63.18% |
Historical Volatility
Volatility is currently contracting